resistant hypertension

Mineralys Therapeutics’ lorundrostat, a novel aldosterone synthase inhibitor, demonstrated strong Phase 3 results in treating resistant hypertension across 1,000+ patients. The trial showed sustained systolic reductions of 19.0 mmHg (11.7 mmHg vs placebo) at 12 weeks and a favorable safety profile with 0.1% serious adverse events. Exceeding FDA efficacy benchmarks, the therapy achieved dual Phase 3 validation and potentially reduces cardiovascular risk by 20-40%. With patent protection through 2041 and a projected $10B+ market opportunity, Mineralys plans Q1 2026 regulatory submission. The company’s $1.2B market cap signals growth potential amid rising global demand for precision hypertension treatments.